First in the worldwide! Oral powder T-1101 approved by the US FDA to start Phase I clinical study
Taivex Therapeutics Corp. has identified a novel targeting small molecule anti-cancer drug, T-1101, which is oral powder for constitution (OPC). T-1101 Investigational New Drug Application (IND) has been submitted in Aug, 2016 and approved by FDA in Sept, 2016. T-1101 is novel oral powder dosage Hec1/Nek2 inhibitor, which block the interaction of Hec1/Nek2 during tumor …